Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment-Reference-Cited by-同舟云学术

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

Published:2018-04 Issue:5 Volume:100 Page:1195-1203
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Kong Xiao-Tang,Nguyen Nhung T.,Choi Yoon J.,Zhang Guicheng,Nguyen HuyTram N.,Filka Emese,Green Stacey,Yong William H.,Liau Linda M.,Green Richard M.,Kaprealian Tania,Pope Whitney B.,Nghiemphu P. Leia,Cloughesy Timothy,Lassman Andrew,Lai Albert

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference20 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

2. A randomized trial of bevacizumab for newly diagnosed glioblastoma;Gilbert;N Engl J Med,2014

3. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;Chinot;N Engl J Med,2014

4. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives;Chen;Curr Cancer Drug Targets,2011

5. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system;Dou;Curr Cancer Drug Targets,2014

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review;Experimental Hematology & Oncology;2024-04-13

2. Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial;Neuro-Oncology;2024-03-19

3. SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction;Briefings in Bioinformatics;2024-01-22

4. Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine;Current Oncology;2023-11-02

5. Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents;Cancers;2023-05-05